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Systematic reviewa b s t r a c t
Rabies is one of themost feared infectious diseases worldwide, predominantly occurring in Asia and Africa
where rabies is endemic in domestic dog populations. Whereas previous studies have demonstrated mass
dog vaccination and post-exposure prophylaxis (PEP) as the most effective control strategies, successful
rabies elimination has yet to be realized as these recognized effective interventions continue to face chal-
lenges of limited accessibility. In the light of newevidence towards improving programmatic feasibility and
clinical practice in rabies control especially among endemic countries, a systematic reviewwas undertaken
to identify cost-effectiveness modelling studies of rabies preventive measures and to provide a critical
reviewof published evidence through comparative evaluation andmodel quality assessment, and a synthe-
sis of key findings based thereon. Our search throughMEDLINE and SCOPUS identified a total of 17 studies
which mostly focused on estimating the impact of increasing PEP and pre-exposure prophylaxis (PrEP)
access, human rabies elimination scenarios using mass dog vaccinations only or complemented with PEP
strategy. While no significant methodological inconsistency across studies was identified and the extent
of reporting is generally high, we note several points for quality and internal validity improvement.
Assessment of modelling approach showed that decision tree models had similar pathways. The results
of the studies suggest that interventions would be cost-effective at the cost-effectiveness threshold of 1
to 3 times per capita Gross Domestic Product (GDP) as recommended by the Commission on
Macroeconomics and Health’s GDP based thresholds, compared with no intervention in rabies endemic
countries. When compared across studies which reported incremental cost-effectiveness ratio (ICER) as
cost per QALY gained or DALY averted in international dollars adjusted by purchasing power parity conver-
sion rate, PEP vaccination yields less cost per DALY averted or QALY gained due to one year-horizon assess-
ment compared to canine vaccination at 4- or 10-year-time horizon.
 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY IGO license.
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Rabies is one of the most feared infectious diseases and is
invariably fatal. The infection spreads through the saliva of the
infected hosts and domestic dogs are the most important vectors
causing human cases [1,2]. The disease is almost always fatal in
both animals and humans. Current estimates suggest that approx-
imately 59,000 human deaths occur each year worldwide [3]. Most
of the deaths occur predominantly in Asia and Africa where rabies
is endemic in domestic dog populations.
A number of rabies elimination strategies have offered tremen-
dous promise for the eradication of this infection. These include
the reduction of dog population density through dog culling; the
reduction of rabies incidence through dog bite management such
as mass dog vaccination, movement ban, pre-exposure prophylaxis
(PrEP) and post-exposure prophylaxis (PEP) for humans bitten by
dogs; and, education of the public and health care providers. Many
scholars presented that controlling rabies in dogs is the most cost-
effective way to prevent rabies humans [4]. However, successful
eradication of canine and human rabies can be achieved with
proper condition.
As previous studies have shown that mass vaccination is the
most efficacious strategy in reducing diseases in all species, mass
dog vaccination is recognized as the most powerful approach in
the prevention of rabies at its transmission source if at least 70%
of the animal population are vaccinated [5]. However, there has
been limited access to dog vaccination campaigns in some under-
served communities. Similarly, access to and affordability of life-
saving PEP, acknowledged as the best possible way to control
rabies in developing nations, is very limited for some reasons in
many parts of Africa and Asia, particularly in rural areas where
most rabies exposures and deaths occur [2,3,6].
Quality data from rabies endemic countries is still scarce. The
World Health Organization (WHO) and other developmental
partners have initiated several work streams to gather available
and new evidence, as well as to undertake epidemiological and
cost-effectiveness modelling. In the light of new evidence
towards improving programmatic feasibility and clinical practice
in rabies control especially among endemic countries, a system-
atic review was undertaken to identify cost-effectiveness mod-
elling studies of all preventive measures for rabies with the
objective of appraising the quality of the individual rabies mod-
els from previous published studies through comparative evalu-
ation and model quality assessment, and generating a synthesis
of key findings based thereon, ultimately towards providing
valuable evidence on the effectiveness of rabies control
strategies.2. Methods
2.1. Search strategy
Health economic modelling studies related to all preventive
measures for rabies were identified through MEDLINE and SCOPUS.
Searches were run since inceptions through 14 June 2017. In addi-
tion, published and unpublished studies identified from a meeting
of the WHO Expert Consultation on Rabies on 26–28th April 2017
in Bangkok, Thailand were included for review. The search terms
‘‘(rabies OR rabid) AND (cost-benefit analysis OR cost OR eco-
nomic)” were used for MEDLINE, and ‘‘(rabies OR rabid) AND
(cost-benefit analysis OR cost OR economic OR cost-effectiveness
OR cost-benefit OR cost-utility)” for SCOPUS.
2.2. Selection of studies
Two reviewers (WR and TA) independently reviewed each article
obtained from databases. Those studies were assessed for relevance
based on title and abstract.We then excluded irrelevant studies that
did not fulfil the following inclusion criteria: (1) studies examining
the economic impact of preventive measures for rabies; (2) inter-
ventions targeted on human and/or dog; and, (3) original cost-
effectiveness studies. Studies such as articles present of experimen-
tal animal models, quantification of rabies virus, genetic analyses,
diagnosis of animal andhuman rabies, immunogenicity studies, vac-
cine safety, and human attitudes and behaviourwere excluded from
the review.All recordswereused to test inter-rater consistency. Per-
centage agreement between two reviewers was 95%, and after dis-
cussions between the two reviewers, a consensus to resolve
potential discrepancies was reached for the final inclusion.
2.3. Data extraction and analysis
Data on details about the research question, the interventions,
populations, study methods, outcomes, discussion and source of
funding were extracted by UC and AJG. We used the frameworks
and templates provided by the WHO Immunization and vaccines
related implementation research advisory committee (IVR-AC) [7]
and Health Intervention and Technology Assessment Program
(HITAP) [7] for the evaluation of methodological variations, quality
assessment and model comparison. In addition, the Consolidated
Health Economic Evaluation Reporting Standards (CHEERS) state-
ment [8]wasused toassess thequalityand transparencyof reporting
of the studies. Reviewers independently assessed the assignedmod-
elling studies, extracted the data employing the standard forms, and
validated the data extraction tables for accuracy and completeness.
780 studies identified from 
Medline
1339 studies identified from 
Scopus
460 studies deleted because of 
duplication
1659 studies were reviewed by titles and 
abstracts.
78 studies were reviewed by full texts.
1584 studies excluded because of
- 586: Not targeted on rabies 
- 7: Other publication types
- 459: No rabies prevention 
- 202: Not targeted on human or dog
- 36: No outcome of interest
- 293: Not modelling studies
- 1: No full text
17 studies eligible for review
3 studies identified from experts (WHO)
and reference tracking 61 studies excluded because of
- 1: Other publication types
- 3: No rabies prevention 
- 4: Not targeted on human or dog
- 2: No outcome of interest
- 8: Not modelling studies
- 2: No full text
- 4: Non English paper
- 24: Costing studies and cost of  illness
- 13:  Mathematic model
Fig. 1. Flowchart of systematic review.
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3.1. Studies included in the analysis
The initial search from MEDLINE and SCOPUS yielded 2119
records. A total of 1584 articles papers were excluded after evalu-
ation of the title and abstract, resulting to 75 short-listed articles.
Three articles were additionally identified from a meeting of the
WHO Expert Consultation on Rabies on 26–28th April 2017 and
by reference tracking. After performing a more detailed full text
examination of the 78 papers, 61 were excluded and resulted in
17 articles which were then included in the review -11 studies
using cost-effectiveness model without dynamic models and 6
studies using cost-effectiveness with dynamic models. A record
of the total number of studies included at each stage of the review
is summarized as a flow chart in Fig. 1.
3.2. General study information
Seventeen economic evaluation studies included in this review
were dated back as early as 1975 to 2017, with a series of publica-
tions starting in 2008 after the release of theWHO recommendation
on rabies vaccine in 2007. The primary research objective of the eco-nomic evaluations can be classified into 4 groups: (1) the estimation
of the impact of increasing access to PEP treatment (7 studies); (2)
the assessment of impact or long-term investment for human rabies
elimination scenarios using mass dog vaccinations only (5 studies);
(3) the estimation of the impact of increasing access to PrEP treat-
ment, (3 studies); and, (4) the evaluation of impact or long-term
investment for human rabies elimination scenarios using mass
dog vaccinations and PEP strategy (2 studies). As presented in
Table 1, majority of the economic evaluation study settings were
conducted among the highly rabies-endemic regions in Africa and
Asia (10 studies). Among the 14 studies with declared funding sup-
port, governmentagencieswerenoted tobe the commonsupporting
source, while others reported to be funded by research aids or agen-
cies, pharmaceutical industry, academic institution, international
non-profit organizations or development partners.
3.3. Study interventions
The most evaluated rabies control intervention among the
assessed economic evaluations was PEP treatment of varying
implementation strategies and scenarios. Four assessments com-
pared PEP strategies i.e., PEP treatment alone or combined PEP
treatment with canine vaccination to no PEP treatment scenario.
Table 1
Summary of study characteristics and different methodologies used in the included
economic evaluations.






Africa and Asia 1 6





University Hospital 1 6
Pharmaceutical industry 1 6
not reported 1 6
Funding source
Government 5 29
Research aids/agencies 3 18
Pharmaceutical industry 2 12
Academe 1 6
Development partners 1 6
International NGO 1 6
Declared no funding 1 6









Life-year gained 3 19
Rabid dog cases averted 2 13
Rabies deaths averted 2 13
QALYs 2 13
Monetary benefit 2 13
Study perspective




Not specified 5 28
Approach of modelling 100
Decision tree model 6 35
Dynamic transmission model 6 35
Other types of models i.e., spreadsheet,
simulation model
2 12
Non modelling i.e., retrospective study 1 6
Not reported 2 12
Time horizon
1 year 3 18
2 years 1 6
4 years 1 6
10 years 7 41
12 years 1 6
Not reported 4 24
Discounting for costs




3%, 5%, and 10% 1 6
N/A 1 6
Not reported 3 18
Discounting for outcomes
No discount 4 25
3% 7 44
5% 1 6
3%, 5%, and 10% 1 6
Not reported 3 19
Types of uncertainty analysis
Univariate analysis alone 5 29
Bivariate analysis alone 1 6
Multivariate analysis alone 2 12
Probabilistic sensitivity analysis alone 1 6
Univariate and Bivariate analysis 1 6
Table 1 (continued)
Study’s characteristics Number of
Studies, n
%
Deterministic and Probabilistic sensitivity
analysis
3 18
Not reported 4 24
T. Anothaisintawee et al. / Vaccine 37 (2019) A146–A153 A149Moreover, PEP treatment was also assessed within a broader rabies
control framework (3 studies). PrEP strategy, on the other hand,
was assessed under varying contexts: one paper specifically
focused its use among travellers heading to rabies-endemic areas;
one study comparing the altered regimens of PrEP; while one study
was a comparative assessment of PrEP versus PEP intervention.
Five papers focused on the impact of canine vaccination only under
varying implementation strategies, coverage scenarios or adminis-
tration frequency.3.4. Quality assessment
3.4.1. Methodological variations
The different methodologies used in the economic evaluations
are presented in Table 1. Of all 17 studies performing economic
evaluation of all preventive measures for rabies using methods
i.e., cost-minimization analysis (CMA) (1 study, 6%), cost-benefit
analysis (CBA) (2 studies, 12%), cost-effectiveness analysis (CEA)
(7 studies, 41%) cost-utility analysis (CUA) (6 studies, 35%) and
both CUA and CBA (1 study, 6%). Among the CEA studies, the out-
comes were reported as life years gained (3 studies, 19%), rabid dog
case averted or rabies death prevented (4 studies, 26%); while CUA
studies generally report their outcome measures in terms of i.e.,
disability adjusted life year (DALY) averted (5 studies, 31%) or qual-
ity adjusted life year (QALY) gained (2 studies, 13%). The most com-
monly applied study’s perspective was government or health
policy-maker (5 studies, 28%), followed by societal viewpoint (4
studies, 22%). Five studies (28%), however, were not explicit with
their evaluation perspective. As regards their modelling technique
to estimate the costs and outcomes, a comparable number of stud-
ies applied either a static decision-tree modelling (6 studies, 35%)
employed by studies which assessed human strategies, or dynamic
transmission modelling technique (6 studies, 35%) used in studies
which evaluated animal strategies. Further, 7 studies (41%) most
commonly applied a 10-year- analytical horizon with a discount-
ing method of 3% both for costs (6 studies, 35%) and outcomes (7
studies, 44%). Among the 14 studies (76%) which performed any
form of uncertainty analysis, the most reported performed method
was univariate analysis alone (5 studies, 29%) or probabilistic with
uni- or bivariate analysis (3 studies, 18%). Studies which have
applied and reported explicit cost-effectiveness threshold
generally followed the WHO-recommended threshold of 3 times
per capita Gross Domestic Product (GDP) to indicate ‘cost-
effective’ interventions, and 1 times per capita GDP for ‘very
cost-effective’ interventions.3.4.2. Sources of input data
Studies have generally referred to previously published litera-
tures for their input parameters on baseline epidemiological data,
vaccine efficacy data and costing data. Regarding clinical effect size
of the interventions, none of the studies have applied or referred to
systematic reviews or meta-analysis in the estimation of efficacy. It
is also noted that five studies assumed 100% vaccine efficacy.
Moreover, one study referred to a panel of experts in the estima-
tion of the probabilities of rabies transmission to a human follow-
ing possible contact with different species of potentially rabid
animals, in the absence of data.
Table 2
Summary of the Extent of Reporting using CHEERS Checklist.
Reporting Items Number of studies which







Background and objectives 17 100
Methods
Target population and subgroups 17 100
Setting and location 17 100
Study perspective 12 71
Comparators 17 100
Time horizon 13 76
Discount rate 12 71
Choice of health outcomes 14
Single study-based estimates 0 82
Synthesis-based estimate 0
Measurement and valuation of
preference based outcomes
4 out of 6 67
Estimating costs and resources
Single study-based estimates 14 82
Synthesis-based estimate 2 12
Currency, price date and
conversion
14 82
Choice of model 10 67
Assumptions 9 60
Results
Study parameters 10 63
Incremental costs and outcomes 12 75
Characterising uncertainty
Single study-based estimates 15 88
Synthesis-based estimate 4 out of 5 80







Source of funding 14 82
Conflicts of interest 6 35
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Among the reporting items in the CHEERS checklist, the back-
ground and rationale, setting and location, target population, com-
parators, and the overall study findings were noted to be the key
domains which were explicitly stated by all studies. Not all studies,
however, have clearly stated the limitations or potential biases in
their assessments. The most unstated information from the studies
is the declaration of potential conflict of interests of the authors
which were reported by only one-third of all the assessed economic
evaluation papers (6 studies, 35%). Other fundamental reporting
domains that were noted to be inadequately discussed in some
papers included the following: (1) key description of model details
(10 studies, 67%) as well their (2) underpinning assumptions (9
studies, 60%); (3) the study parameters with complete information
on the values, ranges, probability distributions applied, and refer-
ences, preferably presented in a tabular format (i.e., 9 studies,
60%); and, (4) the discussion of differences in costs, outcomes or
cost-effectiveness that can be likely explained by variations among
subgroups in the population with different baseline characteristics
or other observedvariability in effects that arenot reduciblebymore
information (11 studies, 65%). Comparing the extent of reporting
across the studies, none was noted to garner a score of less than
50% out of the total key reporting items. The extent of reporting of
the studies following theCHEERS checklist is summarized in Table 2.
3.5. CEA/CUA results
Table 3 demonstrates the results of CEA for rabies preventive
measures. Cost-effectiveness results were reported as the ICER in
terms of cost per rabid dog prevented or averted (2 studies)
[9,10], cost per death prevented or averted (2 studies) [11,12],
and cost per life year gained (LYG) or saved (LVS) (2 studies)
[13,14]. In addition, the CUA results were presented as incremental
cost-effectiveness ratio (ICER) i.e., cost per QALY gained and cost
per DALY averted. At the cost-effectiveness threshold of one times
GDP per capita recommended by the WHO, compared with no PEP
vaccination, PEP vaccination would be more cost-effective based
on societal (27 USD per QALY gained) and healthcare perspectives
(32 USD per QALY gained) in Tanzania [13], whereas PrEP
treatment would be cost-effective compared to PEP vaccination
based on healthcare perspective in the Philippines (25,152 PHP)
[15]. Furthermore, PEP vaccination would be cost-effective in Iran
(233 USD per DALY averted) [16] and Chad (46 USD/DALY averted)
compared with no vaccination [17].
In addition, Bilinski et al. (2016) [18] also found that canine vac-
cination every 2 years with 80% coverage in pastoral area (3,791
USD per DALY averted) or canine vaccination every year with
70% coverage in agro-pastoral areas (2,785 USD per DALY averted)
would be cost-effective at the cost-effectiveness threshold of 1–3
times GDP per capita recommended by the WHO. In addition, com-
prehensive intervention including dog vaccination and culling
would cost 1,401 USD to prevent one DALY compared with base-
line scenario providing healthcare and PEP vaccine only in Sri
Lanka [19]. Similarly, canine vaccination at the target of 100,000
(1,064 USD per DALY averted) and 200,000 dogs (3,694 USD/DALY
averted) would be more cost-effective interventions at the cost-
effectiveness threshold of 1 to 3 times GDP per capita recom-
mended by the WHO in India [20].
To compare the ICER values of all rabies preventive measures
with the unit of outcome as cost per DALY averted or cost per QALY
gained across studies, all ICER values in each country were
adjusted to international dollar values using purchasing power
parity (PPP) in 2016. It was suggested that PEP vaccination yields
less cost per DALY averted or QALY gained (ICERs ranging from
91 to 754 International Dollars per QALY gained or DALY averted)
due to the assessment of a specific time point at one year com-pared to canine vaccination (ICERs ranging from 4,262–
15,880 International Dollars per QALY gained or DALY averted)
during time horizon of 4 or 10 years (Table 4).
3.6. Model comparison
3.6.1. Type of cost-effectiveness modelling
Study designs were retrospective study (1 study, 6%) and mod-
elling approach i.e., decision tree model (6 studies, 35%), dynamic
model (6 studies, 35%). The 4 studies, however, which indicated
the use of deterministic spreadsheet model (2 studies, 12%),
simulation model (1 study, 6%), or model (1 study, 6%), did not ade-
quately report details on their modelling approach. Model compar-
ison in this review focused on decision tree and dynamic
transmission models.
3.6.2. Model structure
3.6.2.1. Decision tree model. There were 6 studies which used deci-
sion tree model structures for CEA (2 study), CUA (3 study), and
CMA (1 study). The CMA study [21] compared rabies pre-
exposure vaccination and serological test strategies (i.e., booster
vaccination was performed at least every 3 years in cases of sero-
conversion at Day 379 + 3 years) compared with the recommended
strategy by the WHO and the Centers for Disease Control and
Prevention (CDC) for both persons at continuous and frequent risk
[21]. Five CEA and CUA studies (83%) used decision tree models to
compare the costs and outcomes of the inventions as follows: (1)
pre-exposure prophylaxis (PrEP) vs no PrEP [11] (1 study), (2) PrEP
Table 3
Summary results of cost-effectiveness analysis for rabies preventive measures.
Study Country Perspective Comparator Interventions ICER
ICER = Cost per rabid dog prevented or averted
1 Frerichs, R. R. and J. Prawda
(1975). [7]
Colombia Not reported No dog
vaccination
70% initial dog vaccination (entire city) 7.42 USD
70% initial dog vaccination + 70% revaccination (yr. 5) (entire city) 4.34 USD
Preferred vaccination policy (VA = 70%) 3.53 USD
2 Wera, E., et al. (2016) [8] Indonesia Government No dog
vaccination
Annual campaigns with short-acting vaccine (immunity duration of
52 weeks) with 70% coverage
3 USD
Annual campaigns with long-acting vaccine (immunity duration of
156 weeks) with 70% coverage
1.81 USD
Biannual campaigns with shortacting vaccine with 70% coverage 2.31 USD
Once-in-2-years campaigns with long-acting vaccine with 70%
coverage
9.38 USD
ICER = Cost per death prevented or averted
1 LeGuerrier, P., et al. (1996)
[9].
Canada Not reported No PrEP
vaccination
PrEP vaccination for travellers 5 billion
CAD










ICER = Cost per life year gained or life year saved
1 Shim, E., et al. (2009) [11] Tanzania Societal No PEP
vaccination
PEP vaccination 555 USD1
Healthcare PEP vaccination 668 USD






In Ngorongoro (pastoral): Canine vaccination with 45% coverage 4227 USD2
In Serengeti (agro-pastoral): Canine vaccination with 90% coverage 3974 USD
PEP vaccine for CII and CIII Dominated
PEP vaccine + RIG only for CIII Dominated
PEP vaccine for CII and vaccine + RIG for CIII Dominated
1 Willingness to pay (WTP) = 1 GDP per capita (1400 USD).
2 WTP = 1-3 GDP per capita ($1430 - $4290).
Table 4
Comparison of the incremental cost-effectiveness ratio (ICER) in international dollar values adjusting by purchasing power parity (PPP) for rabies preventive interventions.
Study Country Perspective Comparator Interventions ICER ICER International $
(PPP) 2016
ICER = Cost per quality adjusted life year (QALY) gained
1 Shim, E., et al. (2009)
[11]
Tanzania Societal No PEP
vaccination
PEP vaccination 27 USD1 91
Healthcare PEP vaccination 32 USD 108




Healthcare PEP vaccination PrEP vaccination 25,152
PHP2
N/A
ICER = Cost per disability adjusted life year (DALY) averted
1 Zinsstag, J., et al. (2009)
[15]
Chad Not reported No PEP
vaccination
PEP vaccination 46 USD 153
2 Hatam, N., et al. (2014)
[14]
Iran Government No PEP
vaccination
PEP vaccination 233 USD3 754
3 Hasler, B., et al. (2014)
[16]
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(2016) [17]
India Government No canine
vaccination
Canine vaccination (100,000 dogs) 1064 USD4 4262
Canine vaccination (200,000 dogs) 3964 USD 15,880
Canine vaccination + sterilization (100,000
dogs)
Dominated
Canine vaccination + sterilization (200,000
dogs)
Dominated
Canine vaccination + female sterilization
(100,000 dogs)
Dominated
Canine vaccination + female sterilization
(200,000 dogs)
Dominated
5 Bilinski, A. M., et al.
(2016) [16]
Tanzania Policymakers No canine
vaccination
In Ngorongoro (pastoral) PEP every 2 years
with 80% coverage
3791 USD5 10,956
In Serengeti (agro-pastoral) PEP every year
with 70% coverage
2785 USD 8048
1 Willingness to pay (WTP) = 1 GDP per capita (1400 USD).
2 WTP = 1 GDP per capita (118,295 PHP).
3 WTP = 1 GDP per capita (12,258 USD).
4 Willingness to pay (WTP) = 1–3 GDP per capita (1582 – 4746 USD).
5 WTP = 1–3 GDP per capita (1610–4830 USD); N/A = not applicable.
T. Anothaisintawee et al. / Vaccine 37 (2019) A146–A153 A151vs post-exposure rabies prophylaxis (PEP) [15] (1 study), and (3)
PEP vs no PEP (3 studies) [13,16,22]. Decision tree model was per-
formed within time horizons of either 1 year (2 studies) or 10 years
(2 studies); however, 2 studies did not report. All 5 studies devel-
oped different decision tree model structures to imitate the pro-
gression of rabies and treatment pattern according to preventive
measures for rabies.3.6.2.2. Transmission dynamic model for cost-effectiveness analy-
sis. There were 6 studies which used transmission dynamic model
to compare cost-effectiveness of rabies preventive interventions
i.e., canine and wildlife vaccination (5 studies) as well as human
PEP (1 study) in rabies endemic regions i.e., Africa (Chad, Tanzania),
Asia (India, Indonesia) and Colombia (Latin America). Fitzpatrick
et al conducted 2 studies in Tanzania [14] and India [20] using the
A152 T. Anothaisintawee et al. / Vaccine 37 (2019) A146–A153compartmental dynamic models. Mostly transmission dynamic
models were consisted of 5 states i.e., susceptible (S), infectious
(I), vaccinated (V) and immune (R) to simulate the dynamics of
dog or wildlife population and rabies virus transmission. Similarly,
Billinski et al (2016) also applied the transmission model adapted
from a dynamic transmission model used in the published study
of Fitzpatrick et al (2014). The study of Wera et al (2016) applied a
deterministic simulation model incorporating the dynamics of a
dog population and rabies virus transmission following the princi-
ples obtained from Hampson et al (2007) and Zinsstag et al
(2009). In addition, another study of Zinsstag et al (2009) conducted
in Chad, Africa also used the dynamic transmission models with 4
compartments of the models for dogs and humans.
4. Discussion
This reviewdetectedareasonablenumberofeconomicevaluations
of different preventive strategies for rabies elimination, withmajority
of the studies focused on the country assessment of the impact of PEP
access after the release of the WHO recommendation on rabies vac-
cine in 2007. Given the endemicity of rabies, the quantity of studies
identified was not expected to be high (only 17 studies), and most
studies (65%) has been performed in Africa and Asia where human
death due to rabies were the highest compared to other regions of
the world. Economic evaluation studies of a variety of rabies preven-
tive interventionswereperformedandcompared interventionswhich
mostly focused on PEP treatment of varying implementation strate-
gies and scenarios, while transmission dynamic modelling primarily
focused on dog vaccination and other dog management strategies.
The main research objectives were related to (1) the estimation of
the impact of increasing access to PEP treatment, (2) the assessment
of impact or long-term investment for human rabies elimination sce-
narios using mass dog vaccinations only, (3) the estimation of the
impact of increasing access to PrEP treatment, and (4) the evaluation
of impact or long-term investment for human rabies elimination sce-
narios using mass dog vaccinations and PEP strategy.
Until now, human rabies deaths have been still occurred espe-
cially in the low resource setting such as countries in Africa andAsia.
Thesemaybe resulted fromthe lackof PEP, reducedvaccination cov-
erage, and lack of people knowledge and awareness of the impor-
tance of PEP vaccination [23,24]. Results from our review suggest
that PEP vaccinationwas themost cost-effective strategy to prevent
humandeath from rabies. This findingwas also compliedwithWHO
strategies that recommend post-exposure treatment for human
rabies prevention. Therefore, increase availability and accessibility
of PEP vaccination, aswell as emphasize health educationandpublic
awareness about the importance of post exposure treatment are the
significant issues to minimize the human death from rabies.
Overall, the quality of methods employed by the economic evalu-
ations is relatively good. Most studies applied CEA or CUAmethods -
the recommended economic evaluation methods to compare costs
and outcomes of rabies preventive measures to inform policy
decision-making [25]. No significant inconsistency across theirmeth-
ods was identified and the extent of reporting based on the CHEERS
checklist is generally high either across individual studies or across
the reporting domains. This may be on account of the fact that while
most studies were focused on low-income country settings where
rabies is endemic, itwasnoted that thefirst authorsweremostly affil-
iated with the academe and institutions from high-income countries
where health economics are relatively well-established.
Nevertheless, there remains to be room for improvement on the
following fundamental economic evaluation domains. First, while
many studies have been found to have considered the efficacy of
the human rabies vaccine [26] in the evaluations, it was noticed that
none has conducted or referred to systematic reviews or meta-
analyses in the estimation of vaccine efficacy. Itwas also highlightedthat five studies assumed 100% vaccine efficacy of human vaccines,
as the efficacy of human rabies vaccine is very high and true vaccine
failures are very rare and mostly related to non-compliance with
recommended procedures of PEP. Second, model specifics and
underpinning assumptions, as well as complete study parameters
and necessary details (i.e., ranges, distribution and references)
should be clearly and completely discussed, as these were not suffi-
ciently reported by all studies. Third, we have noted that only two
papers have reported clear information on the fitting of the model
(i.e., Fitzpatrick et al, 2016 [20] and Zinsstag et al, 2009 [15]). Albeit
not covered in the CHEERS checklist, the internal validity of these
assessmentsmay be improved by discussingmethods onmodel cal-
ibration or validation, as these methods are crucial steps in under-
standing whether the obtained results would be reliable to inform
policy decision-making towards efficiently implementing rabies
preventive measures. Lastly, the failure to adequately stipulate the
study limitations and potential biases along with the discussion of
key findings of the assessed economic evaluations and conflicts of
interest was noted as common gaps and point for improvement
for the reporting quality. Although one-third of all studies did not
report the conflicts of interest statements,we included these studies
for the reason that our systematic review aimed to identify all exist-
ing cost-effectiveness modelling studies of all preventive measures
for rabies, assess the quality of individual rabies models as well as
generate a synthesis of key findings. However, it was noticed that
no conflict of interest statements from such studies might not have
the impact on the outcome of the review, in particularly economic
evaluation results, since these papers were conducted from the
researchers in academic institutions where usually had clear guide-
lines to manage conflicts of interest [11,13,14].
In relation to the comparative assessment of the economic eval-
uation studies on rabies preventive interventions (17 studies)
which applied the modelling approach (12 studies), we found that
decision tree (6 studies) and transmission dynamic (6 studies)
models were used to evaluate costs and outcomes of PEP vaccina-
tion and canine or wildlife related interventions, respectively.
Decision tree models had similar pathways and dynamic transmis-
sion models were similarly demonstrated as a compartmental
model with 5 states i.e., susceptible (S), infectious (I), vaccinated
(V) and immune (R) to simulate the dynamics of dog or wildlife
population and rabies virus transmission.
According to the results of CEA or CUA studies, it was suggested
that rabies preventive interventions would be cost-effective at the
cost-effectiveness threshold of 1 to 3 times per capita GDP as recom-
mendedby theWHO, comparedwithno intervention in rabies ende-
mic countries. Most studies referred the cost-effectiveness
threshold from the Commission on Macroeconomics and Health’s
GDP based thresholds [27]; however, it should be interpreted with
caution that the cost-effectiveness threshold should not be used as
the only criteria for policy decision-making and other criteria such
as affordability, budget impact, fairness, and other important cons-
derations in the local context should also be accounted in a
country-specific process for decision-making [28]. Nevertheless, it
wasnoted that therewere still controversies and limitations inusing
the cost-effectiveness threshold recommended by the Commission
onMacroeconomics andHealth’sGDPbased thresholdswhich could
result in failing to assess and rank interventions within countries
and ignore budget limitations and possibly misleading decision
makers [29]. Therefore, it was suggested that WHO should develop
anew framework for guiding cost-effectiveness threshold especially
low and middle income countries[29].
When compared across studies which reported ICER as cost per
QALY gained or DALY averted in international dollars adjusted by
purchasing power parity conversion rate, it was demonstrated that
PEP vaccination yields less cost per DALY averted or QALY gained
due to the assessment of a specific time point at one year com-
T. Anothaisintawee et al. / Vaccine 37 (2019) A146–A153 A153pared to canine vaccination during time horizon of 4 or 10 years.
This could be explained by the targeted provision of PEP vaccina-
tion administered only to patients who were suspected to be
exposed with rabid animals; whereas higher budget would be
required to invest in canine related rabies preventive measures
such as mass canine vaccination, sterilization, culling, etc.
It is important to address the limitation that this review included
published studies in English language only, thereby eliminating
other possibly available data published as local reports or grey liter-
ature, except one included unpublished report from theGSK vaccine
[15] which was submitted to the WHO Immunization and vaccines
related implementation research advisory committee (IVR-AC).
5. Conclusion
Our review found 17 economic evaluation studies comparing
interventions for rabies elimination. These interventions would
depend from country to country. Most of the interventions focused
on PEP treatment. However, the implementation strategies and
scenarios of PEP treatment were varied in African and Asian coun-
tries. The overall quality of reporting and methods used in eco-
nomic evaluation studies is relatively good. Decision tree models
and dynamic transmission models were applied to evaluate costs
and outcomes of PEP vaccination and canine or wildlife related
interventions, respectively. Generally, rabies preventive interven-
tions would be cost-effective at the cost-effectiveness threshold
of 1 to 3 times per capita GDP as recommended by the WHO,
compared with no intervention in rabies endemic countries. In
addition, PEP vaccination was the most cost-effectiveness strategy
to prevent rabies human death, when compared with other inter-
ventions. However, it should be interpreted with caution that the
cost-effectiveness threshold should not be used as the only criteria
for policy decision-making and there were still controversies and
limitations in using the cost-effectiveness threshold recommended
by the Commission on Macroeconomics and Health’s GDP based
thresholds which could result in failing to assess and rank inter-
ventions within countries and ignore budget limitations and possi-
bly misleading decision makers.
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